Jubilant Pharmova Ltd
JUBLPHARMAJubilant Pharmova Ltd
JUBLPHARMAPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
24.63 | 2.69 | 0.54% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
49.00 | 6.36 | 0.54% |
Forecast & Ratings
Detailed Forecast from 2 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Jubilant Life Sciences Limited is a pharmaceutical and life sciences company.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 5,762.50 | 5,886.29 | 7,557.87 | 9,146.56 | 6,233.67 | 6,389.18 | 6,141.45 | 6,332.30 | 6,795.70 | 7,418.00 | ||||||||||
Raw Materials | 2,157.87 | 2,114.72 | 2,920.96 | 3,523.71 | 1,592.64 | 1,516.38 | 1,550.33 | 1,918.60 | 2,062.50 | 6,072.60 | ||||||||||
Power & Fuel Cost | 366.71 | 333.66 | 424.92 | 466.38 | 112.21 | 105.79 | 134.30 | 166.70 | 148.90 | |||||||||||
Employee Cost | 1,125.09 | 1,230.93 | 1,555.88 | 1,925.96 | 1,843.22 | 1,922.88 | 2,043.39 | 2,166.00 | 2,216.00 | |||||||||||
Selling & Administrative Expenses | 396.06 | 471.69 | 619.21 | 826.54 | 631.50 | 583.30 | 666.14 | 653.90 | 723.20 | |||||||||||
Operating & Other expenses | 456.46 | 365.15 | 478.48 | 909.45 | 281.20 | 594.95 | 589.66 | 657.10 | 820.40 | |||||||||||
EBITDA | 1,260.31 | 1,370.14 | 1,558.42 | 1,494.52 | 1,772.90 | 1,665.88 | 1,157.63 | 770.00 | 824.70 | 1,345.40 | ||||||||||
Depreciation/Amortization | 346.74 | 291.40 | 415.05 | 370.90 | 339.84 | 348.95 | 381.70 | 554.00 | 381.90 | 377.70 | ||||||||||
PBIT | 913.57 | 1,078.74 | 1,143.37 | 1,123.62 | 1,433.06 | 1,316.93 | 775.93 | 216.00 | 442.80 | 967.70 | ||||||||||
Interest & Other Items | 371.35 | 341.11 | 284.28 | 219.81 | 199.71 | 184.10 | 145.49 | 188.20 | 272.30 | 276.30 | ||||||||||
PBT | 542.22 | 737.63 | 859.09 | 903.81 | 1,233.35 | 1,132.83 | 630.44 | 27.80 | 170.50 | 691.40 | ||||||||||
Taxes & Other Items | 150.40 | 161.99 | 216.28 | 329.35 | 335.11 | 296.96 | 216.51 | 88.80 | 93.40 | 98.30 | ||||||||||
Net Income | 391.82 | 575.64 | 642.81 | 574.46 | 898.24 | 835.87 | 413.93 | -61.00 | 77.10 | 593.10 | ||||||||||
EPS | 21.34 | 31.71 | 35.81 | 31.64 | 48.93 | 48.76 | 25.98 | -3.83 | 4.85 | 37.45 | ||||||||||
DPS | 2.60 | 2.60 | 2.60 | 3.91 | 4.34 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | ||||||||||
Payout ratio | 0.12 | 0.08 | 0.07 | 0.12 | 0.09 | 0.10 | 0.19 | — | 1.03 | 0.13 |
Company Updates
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Jubilant Pharmova Ltd | 189.46 | 2.69 | 0.54% |
Sun Pharmaceutical Industries Ltd | 45.65 | 6.52 | 0.74% |
Cipla Ltd | 27.66 | 4.25 | 0.92% |
Torrent Pharmaceuticals Ltd | 66.37 | 16.04 | 0.86% |
Price Comparison
Compare JUBLPHARMA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Jubilant Pharmova Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Quant Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.3146% | Percentage of the fund’s portfolio invested in the stock 1.27% | Change in the portfolio weight of the stock over the last 3 months -0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 26/97 (-3) |
Bandhan Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3889% | Percentage of the fund’s portfolio invested in the stock 0.61% | Change in the portfolio weight of the stock over the last 3 months 0.20% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 165/207 (-1) |
Kotak Special Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3405% | Percentage of the fund’s portfolio invested in the stock 2.20% | Change in the portfolio weight of the stock over the last 3 months 0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 23/44 (-1) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
JUBLPHARMA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.54%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹5.42 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 2, 2024
Dividend/Share
₹5.00
Ex DateEx Date
Aug 2, 2024
Cash Dividend
Ex DateEx DateAug 10, 2023
Dividend/Share
₹5.00
Ex DateEx Date
Aug 10, 2023
Cash Dividend
Ex DateEx DateAug 11, 2022
Dividend/Share
₹5.00
Ex DateEx Date
Aug 11, 2022
Cash Dividend
Ex DateEx DateAug 5, 2021
Dividend/Share
₹5.00
Ex DateEx Date
Aug 5, 2021
Cash Dividend
Ex DateEx DateMar 9, 2020
Dividend/Share
₹5.00
Ex DateEx Date
Mar 9, 2020
Jubilant Pharmova will hold a meeting of the Board of Directors of the Company on 31 January 2025.Powered by Capital Market - Live
In an exchange filing made today, the company informed that the United States Food and Drug Administration (US FDA) had conducted an inspection at the aforementioned facility. Post the inspection, the drug regulator issued five observations with no repeat observations. Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations within stipulated time,' Jubilant Pharmova stated. Jubilant Pharmova is engaged in radiopharma, allergy immunotherapy, CDMO of sterile injectable, generics, contract research development and manufacturing (CRDMO) and proprietary novel drugs businesses. The company's consolidated net profit jumped 64.48% to Rs 102.80 crore on a 4.53% increase in revenue to Rs 1742.20 crore in Q2 FY25 as compared with Q2 FY24. The scrip rose 0.25% to currently trade at Rs 924.20 on the BSE. Powered by Capital Market - Live
Jubilant Pharmova announced that its subsidiary Jubilant Cadista Pharmaceuticals Inc., (Jubilant Cadista)'s solid oral formulations facility at Salisbury, Maryland, USA was inspected by the United States Food and Drug Administration (USFDA). USFDA has issued five observations with no repeat observations. Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations within stipulated time. Going forward the said facility is not expected to manufacture any products as it has closed manufacturing operations as was referenced in the previous disclosure dated 18 April 2024. Powered by Capital Market - Live
Sun Pharma Advanced Research Company Ltd, Five-Star Business Finance Ltd, The Ramco Cements Ltd, Aditya Birla Real Estate Ltd are among the other stocks to see a surge in volumes on BSE today, 16 December 2024.Jubilant Pharmova Ltd notched up volume of 5.34 lakh shares by 10:46 IST on BSE, a 29 fold spurt over two-week average daily volume of 18403 shares. The stock slipped 2.06% to Rs.1,093.20. Volumes stood at 17130 shares in the last session.Sun Pharma Advanced Research Company Ltd saw volume of 2.23 lakh shares by 10:46 IST on BSE, a 8.53 fold spurt over two-week average daily volume of 26087 shares. The stock increased 9.15% to Rs.231.45. Volumes stood at 21924 shares in the last session.Five-Star Business Finance Ltd registered volume of 96529 shares by 10:46 IST on BSE, a 2.68 fold spurt over two-week average daily volume of 36031 shares. The stock rose 3.43% to Rs.671.50. Volumes stood at 38641 shares in the last session.The Ramco Cements Ltd witnessed volume of 37604 shares by 10:46 IST on BSE, a 2.52 times surge over two-week average daily volume of 14922 shares. The stock increased 0.47% to Rs.1,045.80. Volumes stood at 36870 shares in the last session.Aditya Birla Real Estate Ltd clocked volume of 8626 shares by 10:46 IST on BSE, a 2.19 times surge over two-week average daily volume of 3939 shares. The stock gained 2.40% to Rs.2,818.25. Volumes stood at 3690 shares in the last session.Powered by Capital Market - Live
Net profit of Jubilant Pharmova rose 64.48% to Rs 102.80 crore in the quarter ended September 2024 as against Rs 62.50 crore during the previous quarter ended September 2023. Sales rose 4.53% to Rs 1742.20 crore in the quarter ended September 2024 as against Rs 1666.70 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1742.201666.70 5 OPM %16.6114.51 - PBDT250.00194.60 28 PBT158.6098.00 62 NP102.8062.50 64 Powered by Capital Market - Live
Jubilant Pharmova will hold a meeting of the Board of Directors of the Company on 25 October 2024.Powered by Capital Market - Live
The United States Food & Drug Administration (USFDA) conducted an audit of the facility from 28 May to 6 June 2024. The US drug regulatorhas now determined the inspection classification of the facility as 'Voluntary Action Indicated'. Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a subsidiary of Jubilant Pharma, Singapore, a wholly owned subsidiary of the company. Jubilant Pharmova is engaged in radiopharma, allergy immunotherapy, CDMO of sterile injectable, generics, contract research development and manufacturing (CRDMO) and proprietary novel drugs businesses. The company's consolidated net profit stood at Rs 482.10 crore in Q1 FY25, steeply higher than Rs 6.40 crore in Q1 FY24. Total income increased by 9.41% YoY to Rs 1,745.7 crore in Q1 FY25. The counter hit an all time high of 1,060.15 in today's intraday session. Powered by Capital Market - Live
Morepen Laboratories Ltd, La Opala RG Ltd, AGI Greenpac Ltd and Gujarat Alkalies & Chemicals Ltd are among the other gainers in the BSE's 'A' group today, 09 September 2024.Jubilant Pharmova Ltd soared 7.18% to Rs 1020.25 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 72950 shares were traded on the counter so far as against the average daily volumes of 27440 shares in the past one month. Morepen Laboratories Ltd surged 6.90% to Rs 95.5. The stock was the second biggest gainer in 'A' group. On the BSE, 13.81 lakh shares were traded on the counter so far as against the average daily volumes of 33.4 lakh shares in the past one month. La Opala RG Ltd spiked 5.76% to Rs 359.7. The stock was the third biggest gainer in 'A' group. On the BSE, 79605 shares were traded on the counter so far as against the average daily volumes of 11043 shares in the past one month. AGI Greenpac Ltd gained 5.33% to Rs 947.75. The stock was the fourth biggest gainer in 'A' group. On the BSE, 33424 shares were traded on the counter so far as against the average daily volumes of 24883 shares in the past one month. Gujarat Alkalies & Chemicals Ltd exploded 4.97% to Rs 822.2. The stock was the fifth biggest gainer in 'A' group. On the BSE, 29691 shares were traded on the counter so far as against the average daily volumes of 5923 shares in the past one month. Powered by Capital Market - Live
Jubilant Biosys Innovative Research Services,, Singapore (JBIRSPL), subsidiary of Jubilant Biosys (JBL), a wholly owned subsidiary of Jubilant Pharmova, has signed and issued a 'put option offer' to Pierre Fabre Laboratories (PF), which setsforth an offer to acquire 80% equity capital (approx. Euro 4.4 million over a period of 2 years) in a new company to be incorporated in France, which new company shall acquire Pierre Fabre's R&D Centre (Including R&D Site and R&D activities) at Saint Julien, France. The aforesaid contemplated collaboration is subject to prior consultation of the PF works council and approval of the offer by PF, as well as finalization of definitive agreements and customary closing conditions. Post‐closing of the transaction: - New Company would utilize this R&D Centre with capability to collaborate with Big Pharma & Biotech Customers in Europe & USA. - This contemplated transaction would enable JBL to strengthen its drug discovery capabilities in the fields of biologics and antibody drug conjugates (ADC). - PF may invest 20% equity capital (approx. Euro 1.1 million over a period of 2 years) in a new company for a maximum period of 5 years, during which time they may continue to provide support to the new company to transition the R&D Centre into fully independent contract research organization, with PFG having no access to any proprietary information or IP related to the R&D Centre. - PF may also hire services from JBL aggregating to Euro 7 million for first 4 yearsPowered by Capital Market - Live
Firstsource Solutions Ltd, Adani Energy Solutions Ltd, Sapphire Foods India Ltd, Lloyds Metals & Energy Ltd are among the other stocks to see a surge in volumes on NSE today, 01 August 2024.Jubilant Pharmova Ltd recorded volume of 101.02 lakh shares by 14:14 IST on NSE, a 14.89 times surge over two-week average daily volume of 6.78 lakh shares. The stock gained 11.13% to Rs.859.30. Volumes stood at 11.18 lakh shares in the last session.Firstsource Solutions Ltd registered volume of 497.63 lakh shares by 14:14 IST on NSE, a 10.35 fold spurt over two-week average daily volume of 48.08 lakh shares. The stock rose 9.48% to Rs.299.35. Volumes stood at 32.8 lakh shares in the last session.Adani Energy Solutions Ltd witnessed volume of 241.77 lakh shares by 14:14 IST on NSE, a 6.81 times surge over two-week average daily volume of 35.49 lakh shares. The stock increased 11.53% to Rs.1,269.30. Volumes stood at 46.6 lakh shares in the last session.Sapphire Foods India Ltd recorded volume of 9.17 lakh shares by 14:14 IST on NSE, a 6.7 times surge over two-week average daily volume of 1.37 lakh shares. The stock gained 3.13% to Rs.1,703.60. Volumes stood at 1.95 lakh shares in the last session.Lloyds Metals & Energy Ltd saw volume of 34.23 lakh shares by 14:14 IST on NSE, a 6.03 fold spurt over two-week average daily volume of 5.68 lakh shares. The stock increased 7.38% to Rs.785.40. Volumes stood at 4.46 lakh shares in the last session.Powered by Capital Market - Live
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of -5.77%, vs industry avg of 9.04%
Decreasing Market Share
Over the last 5 years, market share decreased from 4.16% to 1.8%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -33.08%, vs industry avg of 15.28%